

SHORT REPORT

# A missense mutation in *ALDH1A3* causes isolated microphthalmia/anophthalmia in nine individuals from an inbred Muslim kindred

Adi Mory<sup>1,2</sup>, Francesc X Ruiz<sup>3</sup>, Efrat Dagan<sup>2,4</sup>, Evgenia A Yakovtseva<sup>3</sup>, Alina Kurolap<sup>1</sup>, Xavier Parés<sup>3</sup>, Jaume Farrés<sup>3</sup> and Ruth Gershoni-Baruch<sup>\*,1,2</sup>

Nine affected individuals with isolated anophthalmia/microphthalmia from a large Muslim-inbred kindred were investigated. Assuming autosomal-recessive mode of inheritance, whole-genome linkage analysis, on DNA samples from four affected individuals, was undertaken. Homozygosity mapping techniques were employed and a 1.5-Mbp region, homozygous in all affected individuals, was delineated. The region contained nine genes, one of which, aldehyde dehydrogenase 1 (*ALDH1A3*), was a clear candidate. This gene seems to encode a key enzyme in the formation of a retinoic-acid gradient along the dorsoventral axis during an early eye development and the development of the olfactory system. Sanger sequence analysis revealed a missense mutation, causing a substitution of valine (Val) to methionine (Met) at position 71. Analyzing the p.Val71Met missense mutation using standard open access software (MutationTaster online, PolyPhen, SIFT/PROVEAN) predicts this variant to be damaging. Enzymatic activity, studied *in vitro*, showed no changes between the mutated and the wild-type *ALDH1A3* protein.

*European Journal of Human Genetics* (2014) 22, 419–422; doi:10.1038/ejhg.2013.157; published online 24 July 2013

**Keywords:** *ALDH1A3* gene; anophthalmia/microphthalmia; homozygosity mapping

## INTRODUCTION

Anophthalmia and microphthalmia (A/M) are rare developmental anomalies resulting in absent or small ocular globes, respectively. Anophthalmia refers to complete absence of the ocular globe in the presence of adnexa (eyelids, conjunctiva and lacrimal apparatus). Microphthalmia is defined as such when the total axial length of the globe is at least two SD below the mean for age; this typically correlates to an axial length below 21 mm in adult eyes.<sup>1,2</sup>

A/M is a heterogenous condition. A/M may affect one or both eyes and present as either an isolated or syndromic disorder.<sup>1,2</sup> Both genetic and environmental factors, such as fetal alcohol syndrome and vitamin A excess or deficiency, contribute to congenital eye defects.<sup>3–7</sup> All types of Mendelian inheritance have been reported for A/M. The majority of genes known to be involved in the pathogenesis of A/M are transcription factors or homeobox genes.<sup>8</sup>

We have previously described a highly inbred Muslim kindred, from Northern Israel, with isolated A/M.<sup>9</sup> Nine affected individuals had isolated bilateral microphthalmia and no light perception. All showed normal intelligence, displayed no other anomalies and were otherwise healthy. Responses on electroretinogram or visually evoked potentials were consistently absent in all cases. Computed tomography scans disclosed small congenital cystic globes, with rudimentary optic nerves and extraocular muscles. This study aimed to unravel the genetic basis underlying A/M in our family.

## METHODS

### Patients and families

Four highly inbred nuclear families of Muslim origin displaying autosomal-recessive, isolated A/M were studied. Thirteen healthy parents and siblings and nine affected individuals were clinically investigated. Blood samples were drawn from all participants. Skin biopsy was obtained from one affected individual. The study was approved by the institutional review board at Rambam Health Care Campus, Haifa. Signed informed consent (self and parental) was obtained.

### Molecular analyses

Using linkage analyses, known A/M causative genes such as *VX2* (MIM:610093), *RAX* (MIM:611038), *SOX2* (MIM:206900) and *PAX6* (OMIM:607108) were excluded. Genomic DNA of four affected individuals (VI\_2, VI\_6, VI\_12 and VI\_13) was genotyped using the Affimetrix GeneChip Human Mapping 250 K Nsp microarray (Santa Clara, CA, USA). Homozygosity-by-descent analysis was carried out manually, exploring identical homozygous intervals in all affected individuals. Linkage analysis, of a candidate homozygous locus on chromosome 15, was expanded to include additional family members, using two microsatellite markers designed by us: GT22 at chr15: 101094111-101094103 (marker\_1:F\_5'-TGT CAA CCA CGA GCA GTT TC-3'; R\_5'-GCC CTC AGC ATC CTG ATA TT-3') and TG24 at chr15:102147332-102147378 (marker\_2:F\_5'-GTG GTG GGC TGA TAA ATG CT; R\_5'-AAC AAA GGC ATT CTG TGA GGA-3'). Haplotypes of family members were manually constructed and analyzed with SUPERLINK online

<sup>1</sup>Institute of Human Genetics, Rambam Health Care Campus, Haifa, Israel; <sup>2</sup>The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel; <sup>3</sup>Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>4</sup>Department of Nursing, University of Haifa, Haifa, Israel  
\*Correspondence: Professor R Gershoni-Baruch, Institute of Human Genetics, Rambam Health Care Campus, Haifa, Israel and The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel. Tel: 972 4 854 2456; Fax: 972 4 854 3029; E-mail: rgershoni@rambam.health.gov.il  
Received 27 March 2013; revised 19 May 2013; accepted 27 May 2013; published online 24 July 2013

under the assumption of autosomal-recessive inheritance and disease allele frequency of 0.01. One candidate gene, aldehyde dehydrogenase 1 (*ALDH1A3*), within the homozygous region was sequenced using genomic DNA from one affected individual. Sanger sequencing of coding regions and flanking intron-exon boundaries was undertaken (primer sequences are available on request). Once the causative mutation was detected (c.211 G>A), a PCR-RFLP assay was developed using primers designed by us: exon3\_F:5'-CAG TCT CTC TCT GTT GTT CTG G-3' and exon3\_R:5'-GAG AGC CGT GTC TCA GAG GA-3'. The G to A substitution abolishes an HpyCH4IV restriction-native site, generating cleavage-differential products for the wild-type (277 bp, 35 bp) and the mutated (312 bp) alleles.

Total RNA was extracted from cultured epidermal fibroblasts using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse transcribed into cDNA by the QuantiTect reverse transcription kit (Qiagen) using RT primer mix according to the manufacturer's protocol. cDNA of *ALDH1A3* was sequenced using primers devised by us: cDNA\_exon2\_F: 5'-GCA ACC TGG AGG TCA AGT TC-3' and cDNA\_exon5\_R: 5'-CAG CTT CCA CAC CAG CAT C-3'.

### Kinetic studies of the p.Val71Met mutation

*ALDH1A3* cDNA was subcloned into the pET-30 Xa/LIC (Novagen, Bloemfontein, South Africa) expression vector, coding for an N-terminal (His)<sub>6</sub> tag, by using two primers containing ligation-independent cloning overhangs, as indicated by the manufacturer (EMD Biosciences, Darmstadt, Germany). All reactions were performed in a DNA thermal cycler with *Phusion* High-Fidelity DNA Polymerase (Thermo Scientific, Waltham, MA, USA). Two mutagenic primers, 5'-GGA GAT AAG CCC GAC ATG GAC AAG GCT GTG GAG GCT GC-3' and 5'-CTC CAC AGC CTT GTC CAT GTC GGG CTT ATC TCC TTC TTC-3', were designed to introduce the p.71Met mutation, using the wild-type *ALDH1A3* cDNA cloned into pET-30 Xa/LIC as a template. Mutated nucleotides are underlined. The procedure was based on the QuikChange Site-Directed Mutagenesis Kit method (Stratagene, Leicester, UK). The mutagenic strands were sequence verified and then transformed into *Escherichia coli* BL21 cells, in which recombinant *ALDH1A3* was expressed at 24 °C and purified, as previously described<sup>10</sup> and as follows: cells were lysed by sonication and the homogenate was applied onto a nickel-charged chelating Sepharose Fast Flow (GE Healthcare, Little Chalfont, UK) column (5 ml). After washing with 60 mM imidazole in 20 mM Tris-HCl, 0.5 M NaCl, pH 8.0, the enzyme was eluted with 250 mM imidazole in the same buffer. Protein fractions were concentrated and imidazole was removed with an Amicon ultra device (Millipore, Little Chalfont, UK). Protein concentration was determined by a dye-binding assay using bovine serum albumin as a standard.<sup>11</sup> Enzymatic activity of *ALDH1A3* was determined in 50 mM HEPES, 50 mM magnesium chloride, 5 mM dithiothreitol, pH 8.5, at 37 °C, and in the presence of a saturating concentration of cofactor NAD<sup>+</sup>. The activity with 4-nitrobenzaldehyde was measured in a Cary 400 Bio (Varian, Palo Alto, CA, USA) spectrophotometer, as described.<sup>12</sup> Activity with retinoids was analyzed by HPLC; after extraction, retinoids were separated by chromatography on a Nova-Pak Silica column in *n*-hexane:methyl-*tert*-butyl ether:isopropanol:acetic acid (95.9:4.0:0.075:0.025, v/v) mobile phase, at a flow rate of 2 ml/min, and separation of retinaldehyde, retinoic acid and retinol was achieved in a single step, with retention times of 6.76, 8.72 and 29.45 min, respectively, based on previously described protocols.<sup>12,13</sup> An *M<sub>r</sub>* of 244 000 was used to calculate the *k<sub>cat</sub>* values. The kinetic constants were expressed as the mean ± SEM of two determinations. In addition to HPLC-based kinetics with retinoids, UV-vis spectrophotometric determination of 4-nitrobenzaldehyde oxidation, in which NAD<sup>+</sup> reduction was measured at 340 nm, was undertaken.

### RESULTS

Whole-genome homozygosity mapping defined a single homozygous segment on chromosome 15q26.3 spanning 1 340 206 bp between rs1552101 and rs6598484 shared by four affected individuals. We thereafter developed and genotyped two microsatellite markers in this interval; all affected individuals (*n* = 9) shared the same homozygote haplotype for marker\_1, all parents (*n* = 8) were heterozygote for the

linked haplotype and healthy siblings (*n* = 5) were either heterozygote or noncarriers of the linked haplotype (Figure 1a). A two-point LOD score of 7.9 was calculated. The region encompassed nine genes, one of which, *ALDH1A3* (NM\_000693.2 (MIM600463)), a key enzyme in the formation of a retinoic-acid gradient along the dorsoventral axis during an early eye development, was sequenced. Sanger sequencing revealed a homozygous missense mutation c.211G>A (p.Val71Met) in an affected individual (Figure 1b). Using PCR-RFLP analyses, the mutation was tested in all parents and healthy siblings from our four related families and was found to cosegregate with the disease; all affected individuals were homozygous for the mutation (*n* = 9; probability for a random amino-acid exchange 3.3147E-06). Unaffected siblings were either heterozygous or noncarriers (*n* = 5), and all parents were heterozygotes (*n* = 8). The mutation was tested and not observed in 100 individuals from the same ethnic origin.

The mutation was not recorded in the dbSNP databases or the Exome Variant Server. MutationTaster online predicts p.Val71Met to be disease causing (probability score: 0.92). SIFT/PROVEAN (San Diego, CA, USA) and PolyPhen2 predict the mutation to be damaging. *ALDH1A3* consists of 13 exons that encode retinaldehyde dehydrogenase, a protein of 512 amino-acid residues involved in retinoic-acid synthesis. Residue 71 is positioned in exon 3, within a DXXDXD motif, between two strictly conserved Asp residues.

The mutation is located at position +7 of exon 3 and does not overlap with the consensus splicing sequence. We, however, have excluded an eventual splicing effect by sequencing the corresponding cDNA from an affected individual. No aberration was identified other than the homozygote G>A substitution.


Wild-type and p.71Met-mutant *ALDH1A3* were expressed as soluble proteins in *E. coli*. Comparable expression levels were observed for the wild-type and p.71Met-mutant *ALDH1A3*, as assessed from the SDS-PAGE analysis of *E. coli* lysates (Figure 2). Similar purification yields and activity loss over time were obtained for the mutant and wild-type protein. Under the purification and storage conditions used, both proteins displayed low stability, and precipitation over time was equivalent. No evidence of misfolding or increased instability was observed for the p.71Met mutant.

Kinetic constants were determined using freshly prepared protein. Both wild-type and p.71Met mutant showed comparable enzymatic activity using NAD<sup>+</sup> as a cofactor. Kinetic analysis revealed that wild-type and mutant protein display similar *K<sub>m</sub>* (0.083 ± 0.01 vs 0.085 ± 0.01 μM) and *k<sub>cat</sub>* (0.79 ± 0.02 vs 0.62 ± 0.02 per min) values for all-*trans*-retinaldehyde. Very small differences in the *K<sub>m</sub>* values for NAD<sup>+</sup> (7.9 ± 1.7 vs 4 ± 0.3 μM) were observed between the wild-type and the mutant enzymes.


UV-vis spectrophotometric determination yielded *V<sub>max</sub>* values for wild-type and p.71Met-mutant *ALDH1A3* of 0.23 and 0.13 μmol per min per mg, respectively.

### DISCUSSION

Nine individuals, from one inbred kindred, segregating isolated A/M with orbital cysts were homozygous for a missense mutation in the gene encoding the A3 isoform of the *ALDH1A3*. The probability for this being a random association stands at 3.8 × 10<sup>-6</sup>. *ALDH1A3* is a key enzyme in the formation of a retinoic-acid gradient along the dorsoventral axis during an early eye development.<sup>3,6,7</sup> Fares-Taie et al<sup>14</sup> have recently shown that mutations in *ALDH1A3* cause A/M. Two missense mutations and one splice mutation, namely, p.Arg89Cys, p.Ala493Pro and c.475 + 1G>T, were reported to segregate in three consanguineous families with A/M. Here, we report on yet another *ALDH1A3* missense mutation, namely,



**Figure 1** Haplotypes and mutation c.211G>A in exon 3 of the *ALDH1A3* gene. (a) Disease-associated haplotypes are shown in boxes. Markers 1 and rs2573582 define the minimal homozygosity locus associated with the disease (allele 0: not genotyped). (b) The *ALDH1A3* c.211G>A (p.Val71Met) mutation in genomic DNA of A/M homozygote individual and carrier.



**Figure 2** SDS-PAGE analysis. Fractions obtained during the purification of wild type (lanes 1–3) and p.71M *ALDH1A3* (lanes 4–6). Protein was stained with Coomassie Brilliant Blue (Bio Rad, Hercules, CA, USA). Lanes 1 and 4, *E. coli* lysate (20 µg); lanes 2 and 5, flowthrough from nickel-charged chelating Sepharose; lanes 3 and 6, fractions eluted with 250 mM imidazole.


p.Val71Met that causes A/M. Although the role of retinoic-acid signaling in the eye development is well established, the results provided by Fares-Taie *et al*<sup>14</sup> and that of ours ascertain the genetic linkage between retinoic-acid synthesis dysfunction and an early eye development anomalies, namely, A/M, in humans.

The mutation described here affects an amino-acid residue that is fairly well conserved in the *ALDH1A1* gene orthologs, as well as in the *ALDH1A2* and *ALDH1A3* gene paralogs. Otherwise, valine (Val) is

replaced by another apolar residue (Ile) in most instances. Thr, an isosteric residue, has also been observed to substitute Val (Figure 3). After assessing the highly similar 3D structures of sheep *ALDH1A1* (PDB code 1BXS) and rat *ALDH1A2* (PDB code 1BI9), we conclude that residue 71 is located at the beginning of an  $\alpha$ -helix in the NAD<sup>+</sup>-binding domain near the protein surface. Apparently, the p.Val71Met substitution should not greatly disturb protein stability or enzymatic function. Methionine (Met) is a rather rare amino acid in proteins, moderately hydrophobic, that similar to Val tends to stabilize  $\alpha$ -helices. Unlike residues 89 and 493, reported by Fares-Taie *et al*,<sup>14</sup> Val71 is not involved in subunit–subunit interactions.

Our kinetic assays delivered comparable expression and activity levels for the wild-type and mutant *ALDH1A3* proteins. To our knowledge, this report is the first to provide kinetic constants of human *ALDH1A3* and retinaldehyde. It has been reported that oxidative stress may render Met susceptible to oxidation, in the process yielding hydrophilic Met sulfoxide and Met sulfone, which can destabilize  $\alpha$ -helices. Solvent-exposed Met residues are much more susceptible to oxidation than buried ones, and this may lead to protein misfolding, lower thermal stability or altered activity.<sup>15</sup> It is conceivable that the reductive environment of the *E. coli* cytosol and the low growth temperature *in vitro* prevented the oxidation and subsequent instability of the recombinant enzyme. It is also likely that conditions used during the purification and enzymatic assay protected Met from being oxidized. Thus, enhanced sensitivity of the p.71Met mutant to oxidation, if the case, might have passed undetected in our assays. Val to Met substitutions were indeed reported to increase temperature sensitivity in other proteins.<sup>16,17</sup> Likewise, a p.Thr49Met mutation in retinol dehydrogenase 12, which reduces retinaldehyde to retinol, was reported to cause severe retinal degeneration.<sup>18</sup> This protein, which





**Figure 3** Amino-acid sequence alignment of ALDHs from different organisms and other ALDH paralogs. Amino acid Val71 is highlighted with an arrow.

retained significant catalytic activity *in vitro*, demonstrated higher instability linked to proteasome degradation in the cell.<sup>18</sup>

The dynamics of the p.Val71Met mutation remain elusive at this stage. It is plausible that the Met to Val substitution at codon 71 may constitute a secondary initiation for translation mechanisms, or alternately the mutation may cause abnormal protein folding. Further studies on thermal stability, protease sensitivity or *in vivo* turnover rate of the p.71Met mutant could provide additional information.

Microphthalmia, a strong manifestation within the fetal alcohol spectrum disorder,<sup>19</sup> is attributed to a competitive effect of ethanol, or its metabolite acetaldehyde, for retinaldehyde dehydrogenase.<sup>20,21</sup> We could assume that A/M, caused by defects in *ALDH1A3*, is the genetic alternative of this disorder.

Thus far, the mutations described have been associated with nonsyndromic A/M. The families reported by Fares-Taie *et al*<sup>14</sup> have inconsistently demonstrated additional features (autism and heart anomalies), which may be mutation related or incidental. Fares-Taie *et al*<sup>14</sup> question the validity of these additional signs. In our families, all affected cases had isolated A/M and normal intelligence. Recently, homozygosity for two nonsense mutations in *ALDH1A3*, namely, c.568A>G (p.Lys190\*) and c.1165A>T (p.Lys389\*), that predict nonsense-mediated decay and complete loss of function were linked to anophthalmia and hypoplasia of the optic nerve and optic chiasma. With this in mind it remains speculative whether missense mutations are preferentially associated with microphthalmia, whereas nonsense and frameshift mutations are linked to anophthalmia.<sup>22</sup>

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**

We are grateful to all family members for their participation in this study. We thank Gregg Duester who provided the *ALDH1A3* cDNA clone. Affymetrix GeneChip Human Mapping 250K Nsp microarray was carried out in the Biological Services Unit at the Weizmann Institute. This work was supported in part by the Spanish Ministerio de Economía y Competitividad (BFU2011-24176) and Generalitat de Catalunya (2009 SGR 795).

- 3 Lee LM, Leung CY, Tang WW *et al*: A paradoxical teratogenic mechanism for retinoic acid. *Proc Natl Acad Sci USA* 2012; **109**: 13668–13673.
- 4 Hornby SJ, Ward SJ, Gilbert CE, Dandona L, Foster A, Jones RB: Environmental risk factors in congenital malformations of the eye. *Ann Trop Paediatr* 2002; **22**: 67–77.
- 5 Yelin R, Schyr RB, Kot H *et al*: Ethanol exposure affects gene expression in the embryonic organizer and reduces retinoic acid levels. *Dev Biol* 2005; **279**: 193–204.
- 6 Duester G: Keeping an eye on retinoic acid signaling during eye development. *Chem Biol Interact* 2009; **178**: 178–181.
- 7 Molotkov A, Molotkova N, Duester G: Retinoic acid guides eye morphogenetic movements via paracrine signaling but is unnecessary for retinal dorsoventral patterning. *Development* 2006; **133**: 1901–1910.
- 8 Bardakjian TM, Schneider A: The genetics of anophthalmia and microphthalmia. *Curr Opin Ophthalmol* 2011; **22**: 309–313.
- 9 Porges Y, Gershoni-Baruch R, Leibur R *et al*: Hereditary microphthalmia with colobomatous cyst. *Am J Ophthalmol* 1992; **114**: 3.
- 10 Ruiz FX, Porté S, Gallego O *et al*: Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily. *Biochem J* 2011; **440**: 335–344.
- 11 Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; **72**: 248–254.
- 12 Gallego O, Belyaeva OV, Porté S *et al*: Kinetic Analysis of SDRs, ADHs and AKRs toward Free and CRBP1-bound Retinoids: Effect of Tween-80 and Microsomal Membranes; in Weiner H, Lindahl R, Maser E, Plapp B (eds) *Enzymology and Molecular Biology of Carbonyl Metabolism 13*. West Lafayette, IN, USA: Purdue University Press, 2007, pp 144–151.
- 13 Barua AB: Improved normal-phase and reversed-phase gradient high-performance liquid chromatography procedures for the analysis of retinoids and carotenoids in human serum, plant and animal tissues. *J Chromatogr A* 2001; **936**: 83.
- 14 Fares-Taie L, Gerber S, Chassaing N *et al*: *ALDH1A3* mutations cause recessive anophthalmia and microphthalmia. *Am J Hum Genet* 2013; **92**: 265–270.
- 15 Wolschner C, Giese A, Kretzschmar HA, Huber R, Moroder L, Budisa N: Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein. *Proc Natl Acad Sci USA* 2009; **106**: 7756–7761.
- 16 Egan MF, Goldberg TE, Kolachana BS *et al*: Effect of COMT Val<sup>108/158</sup> Met genotype on frontal lobe function and risk for schizophrenia. *Proc Natl Acad Sci USA* 2001; **98**: 6917–6922.
- 17 Egan MF, Kojima M, Callicott JH *et al*: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003; **112**: 257–269.
- 18 Lee SA, Belyaeva OV, Kedishvili NY: Disease-associated variants of microsomal retinol dehydrogenase 12 (RDH12) are degraded at mutant-specific rates. *FEBS Lett* 2010; **584**: 507–510.
- 19 Strömmland K, Pinazo-Durán MD: Ophthalmic involvement in the fetal alcohol syndrome: clinical and animal model studies. *Alcohol Alcohol* 2002; **37**: 2–8.
- 20 Kot-Leibovich H, Fainsod A: Ethanol induces embryonic malformations by competing for retinaldehyde dehydrogenase activity during vertebrate gastrulation. *Dis Model Mech* 2009; **2**: 295–305.
- 21 Dupé V, Matt N, Garnier JM, Chambon P, Mark M, Ghyselinck NB: A newborn lethal defect due to inactivation of retinaldehyde dehydrogenase type 3 is prevented by maternal retinoic acid treatment. *Proc Natl Acad Sci USA* 2003; **100**: 14036–14041.
- 22 Yahyavi M, Abouzeid H, Gawdat G *et al*: *ALDH1A3* loss of function causes bilateral anophthalmia/microphthalmia and hypoplasia of the optic nerve and optic chiasma. *Hum Mol Genet* 2013; **22**: 3250–3258.

- 1 Verma AS, Fitzpatrick DR: Anophthalmia and microphthalmia. *Orphanet J Rare Dis* 2007; **2**: 47.
- 2 Schittkowski MP, Guthoff RF: Systemic and ophthalmological anomalies in congenital anophthalmic or microphthalmic patients. *Br J Ophthalmol* 2010; **94**: 487–493.